DES and sarcoma: A study [28] on 28 SFT cases found that INSM1 was reactive in 21% (6/28) of the cases, which was slightly superior to desmin (14.3%, 4/28) and p16 (17.9%, 5/28), suggesting differential diagnosis of sarcomas can be supplemented by the use of the INSM1 marker.